BergenBio Fundamentale Forhold (BGBIO)

drdr · februar 23, 2021, 7:22pm

Så vi snakker om daglig Bem. som en av de faste medisiner livslang som skal hindre graftrejection hos TX pasienter (hjerte og sannsynlig andre transplantadjonsfoemer)! Det blir en stor dag for slik pasientgruppe (og BB investorer)

TekBot · februar 23, 2021, 8:36pm

BERGENBIO ASA: Board approval of 2020 annual financial statement

Bergen, Norway - 23 February 2021: The Board of Directors in BerGenBio ASA (the
“Company”) (OSE:BGBIO) today approved the 2020 annual financial statements
prepared in accordance with International Financial Reporting Standards (IFRS).
…

Vis børsmeldingen

The financial statements are in accordance with the preliminary 2020 annual
financial statements published on 10 February 2021.

The annual report 2020 will be made available on BerGenBio ASA’s
website www.bergenbio.com on 25 February 2021. BerGenBio ASA’s annual general
meeting is planned to be held on 19 March 2021.

END -

Contacts

Richard Godfrey, CEO, BerGenBio ASA
+47 917 86 304

Rune Skeie, CFO, BerGenBio ASA
rune.skeie@bergenbio.com
+47 917 86 513

This information is subject to the disclosure requirements pursuant to section 5
-12 of the Norwegian Securities Trading Act.

Kilde

TekBot · februar 25, 2021, 2:37pm

BERGENBIO ASA: ANNUAL REPORT 2020

Bergen, Norway - 25 February 2021: Reference is made to the notice on 23
February 2021 and the Board of Directors approval of BerGenBio ASA’s (OSE:BGBIO)
Annual Financial statement. The Annual Report for 2020 is available on the
…

Vis børsmeldingen

Company’s website: BerGenBio - Investors

END -

For further information, please contact:

Richard Godfrey, CEO, BerGenBio ASA
+47 917 86 304

Rune Skeie, CFO, BerGenBio ASA
rune.skeie@bergenbio.com
+47 917 86?513

Forward looking statements

This announcement may contain forward-looking statements, which as such are not
historical facts, but are based upon various assumptions, many of which are
based, in turn, upon further assumptions. These assumptions are inherently
subject to significant known and unknown risks, uncertainties and other
important factors. Such risks, uncertainties, contingencies and other important
factors could cause actual events to differ materially from the expectations
expressed or implied in this announcement by such forward-looking statements.

This information is subject to the disclosure requirements pursuant to section 5
-12 of the Norwegian Securities Trading Act.

Kilde

TekBot · februar 25, 2021, 3:02pm

BERGENBIO ASA: NOTICE OF ANNUAL GENERAL MEETING

Bergen, Norway - 25 February 2021: BerGenBio ASA (OSE:BGBIO) will be holding its
Annual General Meeting [virtually] on 19 March 2021 at 15:00 hours (CET).

…

Vis børsmeldingen

The notice, registration form, power of attorney and proposal from Nomination
Committee are attached to this release. The notice will be sent to all
registered shareholders and is available on the Company’s
website: General Meetings - BerGenBio

All shareholders are encouraged to exercise their shareholder rights, either
through advance electronically voting through VPS Investor Services, by
using the enclosed proxy form to provide proxy to the Chairman Sveinung Hole (or
the person he appoints), or to attend the general meeting virtually.

Advance vote or proxy for the Annual General Meeting can be registered through
the company’s website or VPS Investor Service within 16 March at 16:00 hours
(CET). Virtual participants need to be logged in to the meeting before 15:00
hours (CET) 19 March 2021.

All shareholders will receive a reference number and pin code required for
registration through the company’s website. Reference number and pin code will
be received either by VPS Investor Service or by post depending if the
shareholder is registered as an electronic user.

We encourage all shareholders to register as electronical user in VPS to
save environment impact.

END -

About?BerGenBio?ASA

BerGenBio?is a clinical-stage biopharmaceutical company focused on developing
transformative drugs targeting AXL as a potential cornerstone of therapy for
aggressive diseases, including immune-evasive, therapy resistant cancers. The
company’s proprietary lead candidate,?bemcentinib, is a potentially first-in
-class selective AXL inhibitor in a broad?phase II clinical development
programme focused on combination and single agent therapy in lung cancer,
leukaemia and COVID-19. A first-in-class functional blocking anti-AXL
antibody,?tilvestamab, is undergoing?phase I clinical testing. In
parallel,?BerGenBio?is developing?a?companion diagnostic test to identify
patient populations most likely to benefit from?bemcentinib: this is expected to
facilitate more efficient registration trials supporting a precision medicine
-based commercialisation strategy.

BerGenBio?is based in Bergen, Norway with a subsidiary in Oxford, UK. The
company is listed on the Oslo Stock Exchange (ticker: BGBIO). For more
information, visit?www.bergenbio.com

Contacts

Richard Godfrey, CEO, BerGenBio ASA
+47 917 86 304

Rune Skeie, CFO, BerGenBio ASA
rune.skeie@bergenbio.com
+47 917 86?513

Forward looking statements

This announcement may contain forward-looking statements, which as such are not
historical facts, but are based upon various assumptions, many of which are
based, in turn, upon further assumptions. These assumptions are inherently
subject to significant known and unknown risks, uncertainties and other
important factors. Such risks, uncertainties, contingencies and other important
factors could cause actual events to differ materially from the expectations
expressed or implied in this announcement by such forward-looking statements.

This information is subject to the disclosure requirements pursuant to section 5
-12 of the Norwegian Securities Trading Act.

Kilde

Rolsu · februar 25, 2021, 8:33pm

Noen som har lest hele enda?

Fra side 17: Near Term Goals - H1 2021:

COVID-19: Trial and Key Secondary End Point data
AML: Proof of Concept data
MDS: Proof of Concept data

Fra side 29: “Bemcentinib has presented a unique dual mechanism of action to combat COVID-19 infection”

Fra side 23: “Comparing oncology drugs developed with a biomarker vs those without showed an almost seven-fold improvement (10.7% vs 1.6%)”
Fra side 34: “Probability of success for a drug development programme is greatly improved in the presence of a biomarker”
Fra side 24: “BerGenBio is also developing predictive biomarkers and companion diagnostics to identify patients most likely to respond to treatment…”

Fra side 46: “In a time where many businesses have struggled, BerGenBio has been fully operational all year, without the need for government grants, and expanding as it prepares for late-stage asset development.”

Tekspert · mars 1, 2021, 10:00am

Hver måned kårer jeg det jeg kaller Teksperter™ for noen av de mest populære investeringene våre

Det er de 3 medlemmene som har fått flest likes på innleggene sine de siste 90 dagene. Teksperter™ får også en unikt merke på profilen sin og et trofé-ikon ved siden av navnet sitt. Du kan bli Tekspert™ i flere aksjer/investeringer, og troféet vil bare vises i tråder der du er Tekspert™.

Her er denne månedens Teksperter™ og det mest likte innlegget deres fra de siste 90 dagene:

@Londonmannen (189 likes)

@anon28800809 (148 likes)

@Mykle (148 likes)

Resten av topp 10:

@HeldigFyr (133 likes)
@drdr (123 likes)
@Ekornet (116 likes)
@Hfyh (106 likes)
@Savepig (101 likes)
@eiken (99 likes)
@Fornybar (96 likes)

Gratulerer!

TekBot · mars 2, 2021, 4:01pm

BerGenBio ASA: Increase of share capital, exercise of share options

Bergen, Norway, 2 March 2021: The Board of Directors in BerGenBio ASA (the
“Company”) (OSE: BGBIO) have, to fulfil the Company’s obligations under the
share option agreements and in accordance with the authorization granted by the
…

Vis børsmeldingen

general meeting on 16 March 2020, resolved to increase the Company’s share
capital by NOK 56,159.90 by issuance of 561,599 new shares. The new shares are
subscribed for by an option holder who has requested and is entitled to exercise
options in accordance with the Company’s option scheme. The subscription price
is in accordance with the prevailing options price pursuant to the Company´s
option scheme, at an average of NOK 14.82 per share. The options that have been
exercised would have expiry 31[st] March 2021, if not exercised.

The capital increase is expected to be registered within 7 days, and following
the issuance of the new shares, the issued share capital of BerGenBio ASA will
be NOK 8,782,158.20 consisting of 87,821,582 shares, each with a par value of
NOK 0.10.

-End-

Contacts

Richard Godfrey

CEO, BerGenBio ASA

ir@bergenbio.com

Rune Skeie

CFO, BerGenBio ASA

rune.skeie@bergenbio.com

+47 917 86 513

Forward looking statements

This announcement may contain forward-looking statements, which as such are not
historical facts, but are based upon various assumptions, many of which are
based, in turn, upon further assumptions. These assumptions are inherently
subject to significant known and unknown risks, uncertainties and other
important factors. Such risks, uncertainties, contingencies and other important
factors could cause actual events to differ materially from the
expectations expressed or implied in this announcement by such forward-looking
statements.

This information is subject to the disclosure requirements pursuant to section 5
-12 of the Norwegian Securities Trading Act.

Kilde

TekBot · mars 4, 2021, 6:01am

BERGENBIO CLOSES RECRUITMENT INTO TRIAL ASSESSING BEMCENTINIB IN COVID-19 PATIENTS

Bergen, Norway, 4[th] March 2021?- BerGenBio ASA (OSE:BGBIO), a clinical-stage
biopharmaceutical company developing novel, selective AXL kinase inhibitors for
severe unmet medical need, is pleased to announce it has closed recruitment into
…

Vis børsmeldingen

the company sponsored randomised Phase II clinical trial (BGBC020), assessing
the efficacy and safety of bemcentinib for the treatment of hospitalised COVID
-19 patients in South Africa and India.

A total of 114 out of the target 120 hospitalised COVID-19 patients have been
recruited across five sites in South Africa and seven sites in India. 56
patients received bemcentinib (as monotherapy or in combination with standard of
care medication) and 58 patients in a control group (receiving standard of care
treatment only). The trial protocol permits co-administration with other
medicines recommended for treatment of COVID-19, including remdesivir and
dexamethasone. The integrity and statistical power of the data remains intact
and top line clinical results are expected to read out around the end of Q1
2021.

The primary endpoint of the trial is time to clinical improvement of at least
two points (from randomisation) on the WHO nine-point ordinal scale, or live
discharge from the hospital, whichever comes first. Key secondary endpoints
include viral load, clinical markers of disease progression and survival rate.

Richard Godfrey, Chief Executive Officer of BerGenBio, commented: “The incidence
of COVID-19 has fallen significantly in South Africa, so we have taken the
decision to close the study for recruitment in a timely fashion, this allows us
to analyse the data without loss of quality and maintain our momentum in the
development of bemcentinib as a potential treatment for COVID-19. We aim to
share initial data as soon as possible around the end of this quarter and remain
hopeful that bemcentinib can play a role in treating COVID-19 patients and
complement the global vaccination programmes.”

-Ends-

About AXL

AXL kinase is a cell membrane receptor and an essential mediator of the
biological mechanisms underlying life-threatening diseases.

In COVID-19, AXL has two synergistic mechanisms of action, it acts a co-receptor
to ACE2, to which the spike protein of the SARS-CoV-2 virus attaches and enters
the host cell, and AXL expression is upregulated that leads to suppression of
the Type 1 Interferon immune response by host cells and in their environment.
Research data confirms bemcentinib inhibits SARS-CoV-2 host cell entry and
suppresses anti-viral Type I interferon response.

In cancer, increase in AXL expression has been linked to key mechanisms of drug
resistance and immune escape by tumour cells, leading to aggressive metastatic
cancers. AXL suppresses the body’s immune response to tumours and drives
treatment failure across many cancers. High AXL expression defines a very poor
prognosis subgroup in most cancers. AXL inhibitors, such as bemcentinib,
therefore, have potential high value as monotherapy and as the cornerstone of
cancer combination therapy, addressing significant unmet medical needs and
multiple high-value market opportunities. Research has also shown that AXL
mediates other aggressive diseases including fibrosis.

About Bemcentinib

Bemcentinib (formerly known as BGB324), is a potential first-in-class, potent
and highly selective AXL inhibitor, currently in a broad phase II clinical
development programme. It is administered as an oral capsule and taken once per
day. Ongoing clinical trials are investigating bemcentinib in COVID-19, and
multiple solid and haematological tumours, in combination with current and
emerging therapies (including immunotherapies, targeted therapies and
chemotherapy), and as a single agent. Bemcentinib targets and binds to the
intracellular catalytic kinase domain of AXL receptor tyrosine kinase and
inhibits its activity.

About BerGenBio ASA

BerGenBio is a clinical-stage biopharmaceutical company focused on developing
transformative drugs targeting AXL as a potential cornerstone of therapy for
aggressive diseases, including immune-evasive, therapy resistant cancers. The
company’s proprietary lead candidate, bemcentinib, is a potentially first-in
-class selective AXL inhibitor in a broad phase II clinical development
programme focused on combination and single agent therapy in cancer, leukaemia
and COVID-19. A first-in-class functional blocking anti-AXL
antibody, tilvestamab, is undergoing phase I clinical testing. In
parallel, BerGenBio is developing a companion diagnostic test to identify
patient populations most likely to benefit from AXL inhibition: this is expected
to facilitate more efficient registration trials supporting a precision medicine
-based commercialisation strategy.

BerGenBio is based in Bergen, Norway with a subsidiary in Oxford, UK. The
company is listed on the Oslo Stock Exchange (ticker: BGBIO). For more
information, visit?www.bergenbio.com

Contacts

Richard Godfrey CEO, BerGenBio ASA

ir@bergenbio.com

Rune Skeie, CFO, BerGenBio ASA
rune.skeie@bergenbio.com
+47 917 86 513

International Media Relations

Mary-Jane Elliott, Chris Welsh, Lucy Featherstone, Carina Jurs

Consilium Strategic Communications
bergenbio@consilium-comms.com
+44 20 3709 5700

Media Relations in Norway

Jan Petter Stiff, Crux Advisers

stiff@crux.no
+47 995 13 891

Forward looking statements

This announcement may contain forward-looking statements, which as such are not
historical facts, but are based upon various assumptions, many of which are
based, in turn, upon further assumptions. These assumptions are inherently
subject to significant known and unknown risks, uncertainties, and other
important factors. Such risks, uncertainties, contingencies and other important
factors could cause actual events to differ materially from the expectations
expressed or implied in this announcement by such forward-looking statements.

This information is subject to the disclosure requirements pursuant to section 5
-12 of the Norwegian Securities Trading Act.

Kilde

Fornybar · mars 4, 2021, 6:05am

Bra! Få ut datasettet og finn ut om covidsagaen skal fortsette. Data tilgjengelig fra alle pasientene om max 17 dager.

God speed.

"A total of 114 out of the target 120 hospitalised COVID-19 patients have been
recruited across five sites in South Africa and seven sites in India. 56
patients received bemcentinib (as monotherapy or in combination with standard of
care medication) and 58 patients in a control group (receiving standard of care
treatment only) "

TekBot · mars 4, 2021, 8:28am

BerGenBio ASA: Share capital increase

Bergen, Norway, 4[th] March 2021 - Reference is made to the stock exchange
notice published by BerGenBio ASA (the “Company”) (OSE: BGBIO) on 2 March 2021
where the Company announced that the board of directors of the Company had
…

Vis børsmeldingen

resolved to increase the Company’s share capital in connection with the exercise
of options pursuant to the Company’s share option program. A total of 561,599
options were exercised and 561,599 new shares were issued at an average
subscription price of NOK 14.84 per share.

The share capital increase has been duly registered in the Norwegian Register of
Business Enterprises. Following such registration, the Company’s share capital
is NOK 8,782,158.20 divided into 87,821,582 shares, each with a nominal value of
NOK 0.10.

-End-

Contacts

ir@bergenbio.com

Richard Godfrey

CEO, BerGenBio ASA

Rune Skeie

CFO, BerGenBio ASA

+47 917 86 513

Forward looking statements

This announcement may contain forward-looking statements, which as such are not
historical facts, but are based upon various assumptions, many of which are
based, in turn, upon further assumptions. These assumptions are inherently
subject to significant known and unknown risks, uncertainties, and other
important factors. Such risks, uncertainties, contingencies and other important
factors could cause actual events to differ materially from the expectations
expressed or implied in this announcement by such forward-looking statements.

This information is subject to the disclosure requirements pursuant to section 5
-12 of the Norwegian Securities Trading Act.

Kilde

alfred_e_neuman · mars 4, 2021, 12:58pm

Macrophage AXL receptor tyrosine kinase inflames the heart after reperfused myocardial infarction

Published: February 2, 2021
JCI - Macrophage AXL receptor tyrosine kinase inflames the heart after reperfused myocardial infarction (DOI)

Tyro3, AXL, and MerTK (TAM) receptors are activated in macrophages in response to tissue injury and as such have been proposed as therapeutic targets to promote inflammation resolution during sterile wound healing, including myocardial infarction. While the role of MerTK in cardioprotection is well-characterized, the unique role of the other structurally similar TAMs, and particularly AXL, in clinically-relevant models of myocardial ischemia-reperfused infarction (IRI) is comparatively unknown. Utilizing complementary approaches, validated by flow cytometric analysis of human and murine macrophage subsets and conditional genetic loss and gain of function, we uncover a unique maladaptive role for myeloid AXL during IRI in the heart.

Administration of a selective small molecule AXL inhibitor alone improved cardiac healing, which was further enhanced in combination with blockade of MerTK cleavage. These data support further exploration of macrophage TAM receptors as therapeutic targets for myocardial infarction.

The specific and highly selective AXL inhibitor (BGB324) used in our studies is orally bioavailable and has demonstrated favorable safety profiles and activity over prolonged periods of administration in clinical trials for the treatment of cancer in humans.

Given the potential dominance of AXL over MerTK and the relative ease in therapeutic targeting of AXL compared to MerTK cleavage, strategies that inhibit AXL may yield more immediate clinical benefits in cardiovascular disease.

Administration of a selective small molecule AXL inhibitor alone improved cardiac healing, which was further enhanced in combination with blockade of MerTK cleavage.

In conclusion, our findings reveal that AXL aggravates cardiac repair by directing proinflammatory metabolic reprogramming of macrophages and that the mechanism is distinct from MerTK, the latter of which is necessary for macrophage efferocytosis of apoptotic cardiomyocytes to initiate inflammation resolution. These findings support exploration of leveraging macrophage TAM receptors in humans to promote inflammation resolution and limit adverse ventricular remodeling that leads to heart failure.

(Bemcentinib, also known as BGB324 or R428)

Cardio · mars 4, 2021, 2:56pm

Dette er stort, og viser nok en gang potensialet til AXL-inhibitorer i antiinflammatorisk sammenheng.

Jeg tror at det å eie Bgbio-aksjer er som å fiske gjedde i et stille vann. Ingenting skjer og man er nær ved å gi opp før monstergjedda gaper kompromissløst over hele sluken…

TekBot · mars 5, 2021, 6:01am

BERGENBIO ANNOUNCES START OF PHASE 1B TRIAL OF ANTI-AXL ANTIBODY TILVESTAMAB (BGB149)

Bergen, Norway, 5[th] March 2021?- BerGenBio ASA (OSE:BGBIO), a clinical-stage
biopharmaceutical company developing novel, selective AXL kinase inhibitors for
severe unmet medical need, announces the first patient dosed in an international
…

Vis børsmeldingen

Phase Ib trial investigating its first-in-class fully humanised anti-AXL
monoclonal antibody, tilvestamab (BGB149).

The objective of the study is to confirm safety, tolerability and determine a
recommended phase II dose (RP2D) for use in subsequent clinical trials. It is a
multiple ascending dose study, that will focus on establishing tilvestamab’s
safety profile, tolerability and provide an insight into the dose proportional
response with respect to its effectiveness at modulating AXL expression, as
determined by BerGenBio’s proprietary cAXL biomarker diagnostic assay.

The study will be conducted in patients with platinum resistant high-grade
serous ovarian cancer, in which AXL is frequently strongly over expressed. The
research will be conducted at specialist ovarian cancer centres able to perform
serial biopsies in these patients, and thereby providing a comprehensive
understanding of how tilvestamab modulates AXL expression in real time during a
treatment period.

Richard Godfrey, Chief Executive Officer of BerGenBio, said: "We understand that
AXL plays an important role in mediating the aggressive nature of this treatment
resistant cancer. From our Phase Ia study with tilvestamab that was completed
last year, we have an insight into its safety profile, and a safe starting dose
for this first-in-patient study. I am particularly excited that we are able to
conduct this state-of-the-art study collecting serial biopsies from patients
with a similar disease, which will provide high quality data on how tilvestamab
modulates AXL expression. This will inform how we can best use tilvestamab in a
future Phase II program.

-Ends-

About AXL

AXL kinase is a cell membrane receptor and an essential mediator of the
biological mechanisms underlying life-threatening diseases.

In COVID-19, AXL has two synergistic mechanisms of action, it acts a co-receptor
to ACE2, to which the spike protein of the Sars-Cov-2 virus attaches and enters
the host cell, and AXL expression is upregulated that leads to suppression of
the Type 1 Interferon immune response by host cells and in their environment.
Research data confirms bemcentinib inhibits SARS-CoV-2 host cell entry and
promotes the anti-viral Type I interferon response.

In cancer, increase in AXL expression has been linked to key mechanisms of drug
resistance and immune escape by tumour cells, leading to aggressive metastatic
cancers. AXL suppresses the body’s immune response to tumours and drives
treatment failure across many cancers. High AXL expression defines a very poor
prognosis subgroup in most cancers. AXL inhibitors, such as bemcentinib,
therefore, have potential high value as monotherapy and as the cornerstone of
cancer combination therapy, addressing significant unmet medical needs and
multiple high-value market opportunities. Research has also shown that AXL
mediates other aggressive diseases including fibrosis.

About tilvestamab

Tilvestamab (BGB149) is a first-in-class, fully humanised, therapeutic anti-AXL
function blocking monoclonal antibody, discovered and developed by BerGenBio. A
Phase Ia study in healthy volunteers has been completed. Pre-clinical data has
shown that tilvestamab prevents AXL mediated cell signalling in cancer models,
reduces cell migration and invasion and shows anti-tumour efficacy.

About BerGenBio ASA

BerGenBio is a clinical-stage biopharmaceutical company focused on developing
transformative drugs targeting AXL as a potential cornerstone of therapy for
aggressive diseases, including immune-evasive, therapy resistant cancers. The
company’s proprietary lead candidate, bemcentinib, is a potentially first-in
-class selective AXL inhibitor in a broad phase II clinical development
programme focused on combination and single agent therapy in lung cancer,
leukaemia and COVID-19. A first-in-class functional blocking anti-AXL
antibody, tilvestamab, is undergoing phase I clinical testing. In
parallel, BerGenBio is developing a companion diagnostic test to identify
patient populations most likely to benefit from AXL inhibition: this is expected
to facilitate more efficient registration trials supporting a precision medicine
-based commercialisation strategy.

BerGenBio is based in Bergen, Norway with a subsidiary in Oxford, UK. The
company is listed on the Oslo Stock Exchange (ticker: BGBIO). For more
information, visit?www.bergenbio.com

Contacts

ir@bergenbio.com

Richard Godfrey CEO, BerGenBio ASA

Rune Skeie, CFO, BerGenBio ASA
rune.skeie@bergenbio.com
+47 917 86 513

International Media Relations

Mary-Jane Elliott, Chris Welsh, Lucy Featherstone, Carina Jurs

Consilium Strategic Communications
bergenbio@consilium-comms.com
+44 20 3709 5700

Media Relations in Norway

Jan Petter Stiff, Crux Advisers

stiff@crux.no
+47 995 13 891

Forward looking statements

This announcement may contain forward-looking statements, which as such are not
historical facts, but are based upon various assumptions, many of which are
based, in turn, upon further assumptions. These assumptions are inherently
subject to significant known and unknown risks, uncertainties, and other
important factors. Such risks, uncertainties, contingencies and other important
factors could cause actual events to differ materially from the expectations
expressed or implied in this announcement by such forward-looking statements

This information is subject to the disclosure requirements pursuant to section 5
-12 of the Norwegian Securities Trading Act.

Kilde

TekBot · mars 6, 2021, 8:28am

BERGENBIO PRESENTS PRECLINICAL COVID-19 DATA AT ANNUAL CONFERENCE ON RETROVIRUSES AND OPPORTUNISTIC INFECTIONS (CROI 2021)

Bergen, Norway, 6 March 2021?- BerGenBio ASA (OSE:BGBIO), a clinical-stage
biopharmaceutical company developing novel, selective AXL kinase inhibitors for
severe unmet medical need, today delivered a Science Spotlight oral presentation
…

Vis børsmeldingen

on preclinical COVID-19 data at the annual Conference on Retroviruses and
Opportunistic Infections (CROI), taking place from 6-10 March 2021.

The presentation was led by BerGenBio’s collaborator, Professor Wendy Maury,
Professor of Microbiology and Immunology at the University of Iowa (Iowa City,
USA), who presented data showing that AXL enhances the ability of SARS-CoV-2 to
infect cell lines from the human airway, increasing the amount of virus measured
in those cells. Treating the human cell lines, Vero E6 and human ACE2-expressing
A549 lung cancer cell lines, with the AXL kinase inhibitor, bemcentinib reduces
the amount of SARS-CoV-2 virus infecting these cells, and it does this by
reducing ACE2-mediated viral cell entry by endocytosis, rather than at the cell
surface.

Additionally an in vivo study also measured the effect of bemcentinib to treat a
type of coronavirus which naturally infects mice - murine hepatitis virus (MHV).
In this study, not only was bemcentinib found to significantly inhibit the viral
load of MHV found in the liver of these animals, but it also significantly
enhanced signatures of a type I IFN response, a potent mediator of the innate
antiviral response.

In conclusion, the effect of bemcentinib demonstrated potent antiviral effects
in preclinical SARS-CoV-2 and other coronavirus models. Further, the findings
support BerGenBio’s ongoing Phase II trial evaluating bemcentinib for the
treatment of hospitalised COVID-19 patients in South Africa and India.

The presentation will be made available on BerGenBio’s website under
‘Presentations’.

Full details of the presentation are as follows:

Title: Targeting the receptor AXL by bemcentinib prevents SARS-CoV-2 infection

Author: Professor Wendy Maury, Professor of Microbiology and Immunology at the
University of Iowa (Iowa City, USA)

Abstract No. 2672

-Ends-

About AXL

AXL kinase is a cell membrane receptor and an essential mediator of the
biological mechanisms underlying life-threatening diseases.

In COVID-19, AXL has two synergistic mechanisms of action, it acts a co-receptor
to ACE2, to which the spike protein of the Sars-Cov-2 virus attaches and enters
the host cell, and AXL expression is upregulated that leads to suppression of
the Type 1 Interferon immune response by host cells and in their environment.
Research data confirms bemcentinib inhibits SARS-CoV-2 host cell entry and
promotes the anti-viral Type I interferon response.

In cancer, increase in AXL expression has been linked to key mechanisms of drug
resistance and immune escape by tumour cells, leading to aggressive metastatic
cancers. AXL suppresses the body’s immune response to tumours and drives
treatment failure across many cancers. High AXL expression defines a very poor
prognosis subgroup in most cancers. AXL inhibitors, such as bemcentinib,
therefore, have potential high value as monotherapy and as the cornerstone of
cancer combination therapy, addressing significant unmet medical needs and
multiple high-value market opportunities. Research has also shown that AXL
mediates other aggressive diseases including fibrosis.

About Bemcentinib

Bemcentinib (formerly known as BGB324), is a potentially first-in-class
selective AXL inhibitor in a broad phase II clinical development programme.
Ongoing clinical trials are investigating bemcentinib in multiple solid and
haematological tumours, in combination with current and emerging therapies
(including immunotherapies, targeted therapies and chemotherapy), and as a
single agent. Bemcentinib targets and binds to the intracellular catalytic
kinase domain of AXL receptor tyrosine kinase and inhibits its activity.
Increase in AXL function has been linked to key mechanisms of drug resistance
and immune escape by tumour cells, leading to aggressive metastatic cancers.

About BerGenBio ASA

BerGenBio is a clinical-stage biopharmaceutical company focused on developing
transformative drugs targeting AXL as a potential cornerstone of therapy for
aggressive diseases, including immune-evasive, therapy resistant cancers. The
company’s proprietary lead candidate, bemcentinib, is a potentially first-in
-class selective AXL inhibitor in a broad phase II clinical development
programme focused on combination and single agent therapy in lung cancer,
leukaemia and COVID-19. A first-in-class functional blocking anti-AXL
antibody, tilvestamab, is undergoing phase I clinical testing. In
parallel, BerGenBio is developing a companion diagnostic test to identify
patient populations most likely to benefit from AXL inhibition: this is expected
to facilitate more efficient registration trials supporting a precision medicine
-based commercialisation strategy.

BerGenBio is based in Bergen, Norway with a subsidiary in Oxford, UK. The
company is listed on the Oslo Stock Exchange (ticker: BGBIO). For more
information, visit?www.bergenbio.com

Contacts

ir@bergenbio.com

Richard Godfrey CEO, BerGenBio ASA

Rune Skeie, CFO, BerGenBio ASA
rune.skeie@bergenbio.com
+47 917 86 513

International Media Relations

Mary-Jane Elliott, Chris Welsh, Lucy Featherstone, Carina Jurs

Consilium Strategic Communications
bergenbio@consilium-comms.com
+44 20 3709 5700

Media Relations in Norway

Jan Petter Stiff, Crux Advisers

stiff@crux.no
+47 995 13 891

Forward looking statements

This announcement may contain forward-looking statements, which as such are not
historical facts, but are based upon various assumptions, many of which are
based, in turn, upon further assumptions. These assumptions are inherently
subject to significant known and unknown risks, uncertainties, and other
important factors. Such risks, uncertainties, contingencies and other important
factors could cause actual events to differ materially from the expectations
expressed or implied in this announcement by such forward-looking statements

This information is subject to the disclosure requirements pursuant to section 5
-12 of the Norwegian Securities Trading Act.

Kilde

Zuba · mars 6, 2021, 8:44am

Thank you Wendy Maury:clap:

In conclusion, the effect of bemcentinib demonstrated potent antiviral effects
in preclinical SARS-CoV-2 and other coronavirus models. Further, the findings
support BerGenBio’s ongoing Phase II trial evaluating bemcentinib for the
treatment of hospitalised COVID-19 patients in South Africa and India.

TekBot · mars 6, 2021, 10:14am

BERGENBIO PRESENTS PRECLINICAL COVID-19 DATA AT ANNUAL CONFERENCE ON RETROVIRUSES AND OPPORTUNISTIC INFECTIONS (CROI 2021)

Bergen, Norway, 6[th] March 2021?- BerGenBio ASA (OSE:BGBIO), a clinical-stage
biopharmaceutical company developing novel, selective AXL kinase inhibitors for
severe unmet medical need, today delivered a Science Spotlight oral presentation
…

Vis børsmeldingen

on preclinical COVID-19 data at the annual Conference on Retroviruses and
Opportunistic Infections (CROI), taking place from 6-10 March 2021.

The presentation was led by BerGenBio’s scientific collaborator, Professor Wendy
Maury, Professor of Microbiology and Immunology at the University of Iowa (Iowa
City, USA), who presented preclinical data. The data presented included in-vitro
and in-vivo models of SARS-CoV-2 infection that causes COVID-19, and the effect
of bemcentinib treatment in these models.

The effect of bemcentinib was found to prevent infection by SARS-CoV-2, as
assessed by viral transcripts in RNAseq studies, as well as reduce the viral
load by qRT-PCR analysis in human lung epithelial, A549-hACE2 and Vero E6 cell
-line models. Bemcentinib was reported to reduce virus internalization, without
affecting virus binding, by limiting the endosomal entry route to the host
cells. In vivo, bemcentinib was found to significantly reduce murine-hepatitis
-virus liver titers, which is a measure of virus load, and significantly
enhanced signatures of type I IFN response.

In conclusion, the effect of bemcentinib demonstrated potent antiviral effects
in preclinical SARS-CoV-2 and other coronavirus models. Further, the findings
support BerGenBio’s ongoing Phase II trial evaluating bemcentinib for the
treatment of hospitalised COVID-19 patients in South Africa and India.

The presentation will be made available on BerGenBio’s website under ‘Scientific
Presentations 2021’: https://www.bergenbio.com/videos/Wendy-CROI-Talk-5min.mp4

Details of the presentation are as follows:

Title: Targeting the receptor AXL by bemcentinib prevents SARS-CoV-2 infection

Author: Professor Wendy Maury, Professor of Microbiology and Immunology at the
University of Iowa (Iowa City, USA)

-Ends-

About AXL

AXL kinase is a cell membrane receptor and an essential mediator of the
biological mechanisms underlying life-threatening diseases.

In COVID-19, AXL has two synergistic mechanisms of action, it acts a co-receptor
to ACE2, to which the spike protein of the Sars-Cov-2 virus attaches and enters
the host cell, and AXL expression is upregulated that leads to suppression of
the Type 1 Interferon immune response by host cells and in their environment.
Research data confirms bemcentinib inhibits SARS-CoV-2 host cell entry and
promotes the anti-viral Type I interferon response.

In cancer, increase in AXL expression has been linked to key mechanisms of drug
resistance and immune escape by tumour cells, leading to aggressive metastatic
cancers. AXL suppresses the body’s immune response to tumours and drives
treatment failure across many cancers. High AXL expression defines a very poor
prognosis subgroup in most cancers. AXL inhibitors, such as bemcentinib,
therefore, have potential high value as monotherapy and as the cornerstone of
cancer combination therapy, addressing significant unmet medical needs and
multiple high-value market opportunities. Research has also shown that AXL
mediates other aggressive diseases including fibrosis.

About Bemcentinib

Bemcentinib (formerly known as BGB324), is a potential first-in-class, potent
and highly selective AXL inhibitor, currently in a broad phase II clinical
development programme. It is administered as an oral capsule and taken once per
day. Ongoing clinical trials are investigating bemcentinib in COVID-19, and
multiple solid and haematological tumours, in combination with current and
emerging therapies (including immunotherapies, targeted therapies and
chemotherapy), and as a single agent. Bemcentinib targets and binds to the
intracellular catalytic kinase domain of AXL receptor tyrosine kinase and
inhibits its activity.

About BerGenBio ASA

BerGenBio is a clinical-stage biopharmaceutical company focused on developing
transformative drugs targeting AXL as a potential cornerstone of therapy for
aggressive diseases, including immune-evasive, therapy resistant cancers. The
company’s proprietary lead candidate, bemcentinib, is a potentially first-in
-class selective AXL inhibitor in a broad phase II clinical development
programme focused on combination and single agent therapy in cancer, leukaemia
and COVID-19. A first-in-class functional blocking anti-AXL
antibody, tilvestamab, is undergoing phase I clinical testing. In
parallel, BerGenBio is developing a companion diagnostic test to identify
patient populations most likely to benefit from AXL inhibition: this is expected
to facilitate more efficient registration trials supporting a precision medicine
-based commercialisation strategy.

BerGenBio is based in Bergen, Norway with a subsidiary in Oxford, UK. The
company is listed on the Oslo Stock Exchange (ticker: BGBIO). For more
information, visit?www.bergenbio.com

Contacts

ir@bergenbio.com

Richard Godfrey CEO, BerGenBio ASA

Rune Skeie, CFO, BerGenBio ASA
rune.skeie@bergenbio.com
+47 917 86 513

International Media Relations

Mary-Jane Elliott, Chris Welsh, Lucy Featherstone, Carina Jurs

Consilium Strategic Communications
bergenbio@consilium-comms.com
+44 20 3709 5700

Media Relations in Norway

Jan Petter Stiff, Crux Advisers

stiff@crux.no
+47 995 13 891

Forward looking statements

This announcement may contain forward-looking statements, which as such are not
historical facts, but are based upon various assumptions, many of which are
based, in turn, upon further assumptions. These assumptions are inherently
subject to significant known and unknown risks, uncertainties, and other
important factors. Such risks, uncertainties, contingencies and other important
factors could cause actual events to differ materially from the expectations
expressed or implied in this announcement by such forward-looking statements

This information is subject to the disclosure requirements pursuant to section 5
-12 of the Norwegian Securities Trading Act.

Kilde

Hakon · mars 6, 2021, 10:27am

@Savepig dette er noe for twittern din

pleximus83 · mars 7, 2021, 2:59pm

TekBot · mars 8, 2021, 9:00am

BERGENBIO TO PRESENT AT UPCOMING INVESTOR CONFERENCES

Bergen, Norway, 8 March 2021 - BerGenBio ASA (OSE:BGBIO), a clinical-stage
biopharmaceutical company developing novel, selective AXL kinase inhibitors for
severe unmet medical need, is pleased to announce that Richard Godfrey, CEO of
…

Vis børsmeldingen

BerGenBio, will be presenting at the following virtual conferences:

H.C. Wainwright Global Life Sciences Conference

Date: 9-10 March 2021
Presentation available during the conference

Registration for attendees (HCW Events)

Sachs European Life Sciences CEO Forum

Date: 10-11 March 2021
Live presentation, Thursday 11 March at 13:10 CET

Registration for attendees (Registration for 14th ELSF)

Carnegie Nordic Virtual Healthcare Seminar

Date: 12 March 2021
Live presentation, Friday 12 March at 11.15 CET

Presentations will be made available on the Company website in the Presentations
section on the day of the respective events:

www.bergenbio.com/investors/presentations/

END -

About BerGenBio ASA

BerGenBio is a clinical-stage biopharmaceutical company focused on developing
transformative drugs targeting AXL as a potential cornerstone of therapy for
aggressive diseases, including immune-evasive, therapy resistant cancers. The
company’s proprietary lead candidate, bemcentinib, is a potentially first-in
-class selective AXL inhibitor in a broad phase II oncology clinical development
programme focused on combination and single agent therapy in lung cancer,
leukaemia and COVID-19. A first-in-class functional blocking anti-AXL antibody,
tilvestamab, is undergoing phase I clinical testing. In parallel, BerGenBio is
developing companion diagnostic tests to identify patient populations most
likely to benefit from AXL inhibition: this is expected to facilitate more
efficient registration trials supporting a precision medicine-based
commercialisation strategy.

BerGenBio is based in Bergen, Norway with a subsidiary in Oxford, UK. The
company is listed on the Oslo Stock Exchange (ticker: BGBIO). For more
information, visit www.bergenbio.com

Contacts

ir@bergenbio.com

Richard Godfrey CEO, BerGenBio ASA

Rune Skeie, CFO, BerGenBio ASA
rune.skeie@bergenbio.com
+47 917 86 513

International Media Relations

Mary-Jane Elliott, Chris Welsh, Lucy Featherstone, Carina Jurs

Consilium Strategic Communications
bergenbio@consilium-comms.com
+44 20 3709 5700

Media Relations in Norway

Jan Petter Stiff, Crux Advisers

stiff@crux.no
+47 995 13 891

Forward looking statements

This announcement may contain forward-looking statements, which as such are not
historical facts, but are based upon various assumptions, many of which are
based, in turn, upon further assumptions. These assumptions are inherently
subject to significant known and unknown risks, uncertainties and other
important factors. Such risks, uncertainties, contingencies and other important
factors could cause actual events to differ materially from the expectations
expressed or implied in this announcement by such forward-looking statements.

This information is subject to the disclosure requirements pursuant to section 5
-12 of the Norwegian Securities Trading Act.

Kilde

Fornybar · mars 10, 2021, 2:50pm

Shorten har redusert under 0.5%-grensen igjen. Mulig de tok et fundamentalt blikk på selskapet og fant ut hva de holdt på å gjøre.

https://ssr.finanstilsynet.no/Home/Details/NO0010650013

Thank you, @CanonBoy - viktig å være presis.